Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 5, 2010, Pages 449-458

  Proksch, Joel W ^a   Ward, Keith W ^a  

^a BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESIFLOXACIN; BESIVANCE; GATIFLOXACIN; MOXIFLOXACIN; OCULAR ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CIPROFLOXACIN RESISTANT STAPHYLOCOCCUS AUREUS; CIPROFLOXACIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DRUG BLOOD LEVEL; DRUG INSTILLATION; DRUG PENETRATION; DRUG TISSUE LEVEL; EXPERIMENTAL RABBIT; IN VITRO STUDY; LACRIMAL FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; STAPHYLOCOCCUS; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY;

ADMINISTRATION, TOPICAL; ANIMALS; AQUEOUS HUMOR; AREA UNDER CURVE; AZA COMPOUNDS; AZEPINES; CONJUNCTIVITIS, BACTERIAL; EYE; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; QUINOLINES; RABBITS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS;

EID: 77957936651     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0054     Document Type: Article

References (50)

1. Hovding, G. Acute bacterial conjunctivitis. Acta Ophthalmol. 86:5-17, 2008.
2. Rose, P. Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin. Pharmacother. 8:1903-1921, 2007.
3. Centers for Disease Control and Prevention (CDC). Outbreak of bacterial conjunctivitis at a college-New Hampshire, January-March, 2002. MMWR. Morb. Mortal. Wkly. Rep. 51:205-207, 2002.
4. Sheikh, A., and Hurwitz, B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst. Rev. 2006; CD001211.
5. Jensen, H.G., and Felix, C. In vitro antibiotic susceptibilities of ocular isolates in North and South America. In Vitro Antibiotic Testing Group. Cornea 17:79-87, 1998.
6. Brook, I. Anaerobic and aerobic bacterial flora of acute conjunctivitis in children. Arch. Ophthalmol. 98:833-835, 1980.
7. Gigliotti, F., Williams, W.T., Hayden, F.G., et al. Etiology of acute conjunctivitis in children. J. Pediatr. 98:531-536, 1981.
8. Leeming, J.P. Treatment of ocular infections with topical antibacterials. Clin. Pharmacokinet. 37:351-360, 1999.
9. Hammond, R.W., Edmondson, W. Treatment of ocular bacterial infections: an update. J. Am. Optom. Assoc. 68:178-187, 1997.
10. Kurokawa, N., Hayashi, K., Konishi, M., et al. Increasing ofloxacin resistance of bacterial flora from conjunctival sac of preoperative ophthalmic patients in Japan. Jpn. J. Ophthalmol. 46:586-589, 2002.
11. Yamada, M., Yoshida, J., Hatou, S., et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br. J. Ophthalmol. 92:848-851, 2008.
12. Afshari, N.A., Ma, J.J., Duncan, S.M., et al. Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J. Ocul. Pharmacol. Ther. 24: 217-223, 2008.
13. Grasbon, T., Mino de, K.H., and Klauss, V. [Coagulasenegative staphylococci in normal and chronically inflamed onjunctiva]. Ophthalmologe 92:793-801, 1995.
14. Ward, K.W., Lepage, J.F., and Driot, J.Y. Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL- 303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J. Ocul. Pharmacol. Ther. 23:243-256, 2007.
15. Cambau, E., Matrat, S., Pan, X.S., et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother. 63:443-450, 2009.
16. Proksch, J.W., Granvil, C.P., Siou-Mermet, R., et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J. Ocul. Pharmacol. Ther. 25:335-343, 2009.
17. Wright, D.H., Brown, G.H., Peterson, M.L., et al. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683, 2000.
18. Hyatt, J.M., McKinnon, P.S., Zimmer, G.S., et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet. 28:143-160, 1995.
19. Craig, W.A. Does the dose matter? Clin. Infect. Dis. 33 Suppl 3:S233-S237, 2001.
20. Nightingale, C.H. Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics. Pharmacotherapy 25:146S-149S, 2005.
21. Wilhelmus, K.R. Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis. J. Ocul. Pharmacol. Ther. 19:493-499, 2003.
22. Madaras-Kelly, K.J., Ostergaard, B.E., Hovde, L.B., et al. Twenty-four-hour area under the concentration-time curve/ MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 40:627-632, 1996.
23. Ambrose, P.G., Bhavnani, S.M., and Owens, Jr., R.C. Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. North Am. 17:529-543, 2003.
24. Sugioka, K., Fukuda, M., Komoto, S., et al. Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin. Clin. Ophthalmol. 3:553-557, 2009.
25. Levine, J.M., Noecker, R.J., Lane, L.C., et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J. Cataract Refract. Surg. 30:2177-2182, 2004.
26. Levine, J.M., Noecker, R.J., Lane, L.C., et al. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing. J. Ocul. Pharmacol. Ther. 20:210-216, 2004.
27. Richman, J., Zolezio, H., and Tang-Liu, D. Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob. Agents Chemother. 34:1602-1604, 1990.
28. Robertson, S.M., Curtis, M.A., Schlech, B.A., et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv. Ophthalmol. 50 Suppl 1:S32-S45, 2005.
29. Aihara, M., Miyanaga, M., Minami, K., et al. A comparison of fluoroquinolone penetration into human conjunctival tissue. J. Ocul. Pharmacol. Ther. 24:587-591, 2008.
30. Donnenfeld, E.D., Schrier, A., Perry, H.D., et al. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology 101:902-905, 1994.
31. Akkan, A.G., Mutlu, I., Ozyazgan, S., et al. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. Int. J. Clin. Pharmacol. Ther. 35:214-217, 1997.
32. Wagner, R.S., Abelson, M.B., Shapiro, A., et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch. Ophthalmol. 123:1282-1283, 2005.
33. McCulley, J.P., Caudle, D., Aronowicz, J.D., et al. Fourthgeneration fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 113:955-959, 2006.
34. Holland, E.J., Lane, S.S., Kim, T., et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 27:314-319, 2008.
35. Koch, H.R., Kulus, S.C., Roessler, M., et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J. Cataract Refract. Surg. 31:1377-1385, 2005.
36. Solomon, R., Donnenfeld, E.D., Perry, H.D., et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 112:466-469, 2005.
37. Arnold, D.R., Granvil, C.P., Ward, K.W., et al. Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatographytandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867:105-110, 2008.
38. Proksch, J.W., et al. Association for research in vision & ophthalmology. Invest. Ophthalmol. Vis. Sci.50:E-2673, 2009.
39. United States Food and Drug Administration. Dermatologic and Ophthalmic Drugs Advisory Committee. Briefing Package for besifloxacin hydrochloride ophthalmic suspension for the treatment of bacterial conjunctivitis. Bausch and Lomb, Inc. Available at www.fda.gov/ohrms/dockets/ac/ 08/briefing/2008-4397b1- 00-Index.htm (accessed May 18, 2010).
40. Tepedino, M.E., Heller, W.H., Usner, D.W., et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 25:1159-1169, 2009.
41. McDonald, M.B., Protzko, E.E., Brunner, L.S., et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 116:1615-1623.e1, 2009.
42. Mather, R., Stewart, J.M., Prabriputaloong, T., et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am. J. Ophthalmol. 138:554-559, 2004.
43. Owen, G.R., Brooks, A.C., James, O., et al. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues. J. Ocul. Pharmacol. Ther. 23:335-342, 2007.
44. Yagci, R., Oflu, Y., Dincel, A., et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye 21:990-994, 2007.
45. Bowman, L.M., Si, E., Pang, J., et al. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J. Ocul. Pharmacol. Ther. 25:133-139, 2009.
46. Shirasaki, Y. Molecular design for enhancement of ocular penetration. J. Pharm. Sci. 97:2462-2496, 2008.
47. Ahmed, I., and Patton, T.F. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26:584-587, 1985.
48. Acheampong, A.A., Shackleton, M., John, B., et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30:421-429, 2002.
49. Chien, D.S., Homsy, J.J., Gluchowski, C., et al. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res. 9:1051-1059, 1990.
50. Speaker, M.G., Milch, F.A., Shah, M.K., et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 98:639-649, 1991.